UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Characterization of novel MPS1 inhibitors with preclinical anticancer activity

Cell death and differentiation, 2013-11, Vol.20 (11), p.1532-1545

2013

Volltextzugriff (PDF)

Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus

Oncogene, 2010-04, Vol.29 (15), p.2205-2216

2010

Volltextzugriff (PDF)

Isolation of more potent oncolytic paramyxovirus by bioselection

Gene therapy, 2013-01, Vol.20 (1), p.102-111

2013

Volltextzugriff (PDF)

COPANLISIB IN COMBINATION WITH ANTI‐PD‐1 INDUCES REGRESSION IN ANIMAL TUMOR MODELS INSENSITIVE OR RESISTANT TO THE MONOTHERAPIES OF PI3K AND CHECKPOINT INHIBITORS

Hematological oncology, 2017-06, Vol.35 (S2), p.257-258

2017

Volltextzugriff (PDF)

63 Radium-223 dichloride – Efficacy and mode-of-action in a mouse model of prostate cancer bone metastasis

European journal of cancer (1990), 2014-11, Vol.50, p.25-26

2014

Volltextzugriff (PDF)

The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo

Osteoporosis international, 2011-11, Vol.22 (11), p.2887-2893

2011

Volltextzugriff (PDF)

959 The MEK Inhibitor BAY 86-9766 Prolongs Survival in Orthotopic, Syngeneic Animal Models of Hepatocellular Carcinoma and Pancreatic Cancer

European journal of cancer (1990), 2012-07, Vol.48, p.S231-S231

2012

Volltextzugriff (PDF)

MOLECULAR MECHANISMS AND COMBINATION STRATEGIES WITH PI3K AND BTK INHIBITORS TO OVERCOME INTRINSIC AND ACQUIRED RESISTANCE IN PRECLINICAL MODELS OF ABC‐DLBCL

Hematological oncology, 2017-06, Vol.35 (S2), p.403-404

2017

Volltextzugriff (PDF)

Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes

Gene therapy, 2008-03, Vol.15 (5), p.371-383

2008

Volltextzugriff (PDF)

Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties

Oncoimmunology, 2022, Vol.11 (1), p.2037216-2037216

2022

Volltextzugriff (PDF)

Oncogenes Meet Metabolism: From Deregulated Genes to a Broader Understanding of Tumour Physiology

1. Aufl., 2008

Volltextzugriff (PDF)

Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds

Gene, 1995-04, Vol.156 (1), p.119-122

1995

Volltextzugriff (PDF)

Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens

The Journal of experimental medicine, 2001-08, Vol.194 (3), p.285-300

2001

Volltextzugriff (PDF)

Regulatable promoters of Saccharomyces cerevisiae: comparison of transcriptional activity and their use for heterologous expression

Nucleic acids research, 1994-12, Vol.22 (25), p.5767-5768

1994

Volltextzugriff (PDF)

CD4+ T Cells Eliminate MHC Class II-Negative Cancer Cells in vivo by Indirect Effects of IFN-γ

Proceedings of the National Academy of Sciences - PNAS, 1999-07, Vol.96 (15), p.8633-8638

1999

Volltextzugriff (PDF)

138 Combination of PI3K inhibitor BAY 80-6946 with allosteric MEK inhibitor BAY 86-9766 (RDEA119) and with erlotinib for the treatment of non-small cell lung cancer

European journal of cancer supplements, 2010, Vol.8 (7), p.50-50

2010

Volltextzugriff (PDF)

Alternative splicing of fosB transcripts results in differentially expressed mRNAs encoding functionally antagonistic proteins

Genes & development, 1991-07, Vol.5 (7), p.1212-1223

1991

Volltextzugriff (PDF)

495 Pharmacological profile of the novel pan-CDK inhibitor BAY 1000394 in tumor models of human small cell lung cancer, breast and prostate cancer as monotherapy and combination treatment

European journal of cancer supplements, 2010, Vol.8 (7), p.158-158

2010

Volltextzugriff (PDF)

151 Allosteric MEK inhibitor BAY 86-9766 (RDEA119) shows anti-tumor efficacy in mono-and combination therapy in preclinical models of hepatocellular carcinoma and pancreatic cancer

European journal of cancer supplements, 2010, Vol.8 (7), p.53-53

2010

Volltextzugriff (PDF)

140 Combination of PI3K inhibitor BAY 80-6946 and allosteric MEK inhibitor BAY 86-9766 (RDEA119), a promising approach for the treatment of colorectal cancers

European journal of cancer supplements, 2010, Vol.8 (7), p.50-50

2010

Volltextzugriff (PDF)

Importance of Nuclear Localization of Apoptin for Tumor-specific Induction of Apoptosis

The Journal of biological chemistry, 2003-07, Vol.278 (30), p.27729-27736

2003

Volltextzugriff (PDF)

Cloning and functional expression of the human GlcNAc-1-P transferase, the enzyme for the committed step of the dolichol cycle, by heterologous complementation in Saccharomyces cerevisiae

Glycobiology (Oxford), 1998-01, Vol.8 (1), p.77-85

1998

Volltextzugriff (PDF)

Structure of the human TIMP-3 gene and its cell cycle-regulated promoter

Biochemical journal, 1995-10, Vol.311 ( Pt 2) (2), p.549-554

1995

Volltextzugriff (PDF)

A Tumor-specific Kinase Activity Regulates the Viral Death Protein Apoptin

The Journal of biological chemistry, 2002-12, Vol.277 (52), p.50820-50827

2002

Volltextzugriff (PDF)

The Interplay Between MYC and HIF in the Warburg Effect

Ernst Schering Foundation symposium proceedings, 2008-01 (4), p.35-53

2008

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(47)

Publikationsform

Sprache

Englisch
(58)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(35)
Biochemistry & Molecular Biology
(27)
Animals
(26)
Humans
(26)
Oncology
(19)
Molecular Sequence Data
(11)
Amino Acid Sequence
(9)
Mice
(9)
Gene Expression
(8)
Saccharomyces Cerevisiae
(8)
Base Sequence
(7)
Biological And Medical Sciences
(7)
Saccharomyces Cerevisiae - Genetics
(7)
Apoptosis
(6)
Cell Biology
(6)
Fundamental And Applied Biological Sciences. Psychology
(6)
Hematology, Oncology And Palliative Medicine
(6)
Metabolism
(6)
Cell Line, Tumor
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Characterization of novel MPS1 inhibitors with preclinical anticancer activity

Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus

Isolation of more potent oncolytic paramyxovirus by bioselection

COPANLISIB IN COMBINATION WITH ANTI‐PD‐1 INDUCES REGRESSION IN ANIMAL TUMOR MODELS INSENSITIVE OR RESISTANT TO THE MONOTHERAPIES OF PI3K AND CHECKPOINT INHIBITORS

63 Radium-223 dichloride – Efficacy and mode-of-action in a mouse model of prostate cancer bone metastasis

The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo

959 The MEK Inhibitor BAY 86-9766 Prolongs Survival in Orthotopic, Syngeneic Animal Models of Hepatocellular Carcinoma and Pancreatic Cancer

MOLECULAR MECHANISMS AND COMBINATION STRATEGIES WITH PI3K AND BTK INHIBITORS TO OVERCOME INTRINSIC AND ACQUIRED RESISTANCE IN PRECLINICAL MODELS OF ABC‐DLBCL

Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes

Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties

Oncogenes Meet Metabolism: From Deregulated Genes to a Broader Understanding of Tumour Physiology

Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds

Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens

Regulatable promoters of Saccharomyces cerevisiae: comparison of transcriptional activity and their use for heterologous expression

CD4+ T Cells Eliminate MHC Class II-Negative Cancer Cells in vivo by Indirect Effects of IFN-γ

138 Combination of PI3K inhibitor BAY 80-6946 with allosteric MEK inhibitor BAY 86-9766 (RDEA119) and with erlotinib for the treatment of non-small cell lung cancer

Alternative splicing of fosB transcripts results in differentially expressed mRNAs encoding functionally antagonistic proteins

495 Pharmacological profile of the novel pan-CDK inhibitor BAY 1000394 in tumor models of human small cell lung cancer, breast and prostate cancer as monotherapy and combination treatment

151 Allosteric MEK inhibitor BAY 86-9766 (RDEA119) shows anti-tumor efficacy in mono-and combination therapy in preclinical models of hepatocellular carcinoma and pancreatic cancer

140 Combination of PI3K inhibitor BAY 80-6946 and allosteric MEK inhibitor BAY 86-9766 (RDEA119), a promising approach for the treatment of colorectal cancers

Importance of Nuclear Localization of Apoptin for Tumor-specific Induction of Apoptosis

Cloning and functional expression of the human GlcNAc-1-P transferase, the enzyme for the committed step of the dolichol cycle, by heterologous complementation in Saccharomyces cerevisiae

Structure of the human TIMP-3 gene and its cell cycle-regulated promoter

A Tumor-specific Kinase Activity Regulates the Viral Death Protein Apoptin

The Interplay Between MYC and HIF in the Warburg Effect

Suchergebnisse filtern